MUCOSOLVAN IN THE TREATMENT OF PATIENTS WITH PRIMARY SJÖGREN'S SYNDROME

Abstract
Patients with primary Sjogern''s syndrome were randomized to mucosolvan (60 mg .times. 2 daily) or placebo, in a double-blind cross-over study. Each period of treatment was 3 wk with 1 wk wash-out in between. None of the objective ophthalmological tests (Schirmer-1-test, break-up time, van Bijsterveld score, cornea sensitivity, appearance of nuclear chromatin in conjunctival epithelial cells, tear lysozyme) improved during the investigation period.